MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the presentation of the first clinical trial data for its telomerase inhibitor cancer drug, GRN163L, at the 18th EORTC-NCI-AACR International Conference on “Molecular Targets and Cancer Therapeutics” in Prague.
